Objective To compare the efficacy of bortezomib+cyclophosphamide+dexamethasone(BCD)and bort-ezomib+lenalidomide+dexamethasone(VRD)regimens in the treatment of patients with multiple myeloma(MM).Method According to different chemotherapy regimens,105 MM patients were divided into BCD group(n=55)and VRD group(n=50).The clinical efficacy,quality of life[European Organization for Research and Treatment of Cancer quality of life questionnaire core 30(EORTC QLQ-C30)],incidence of adverse reactions and prognosis were compared between the two groups.Result The objective response rate of VRD group was higher than that of BCD group,and the total incidence of adverse reactions was lower than that of BCD group,and the differences were statistically significant(P<0.05).After treatment,the scores of each dimension of EORTC QLQ-C30 in both groups were higher than those be-fore treatment,and the scores of each dimension of EORTC QLQ-C30 in VRD group were higher than those in BCD group,and the differences were statistically significant(P<0.05).After 6 months of follow-up,there were no significant differences in survival rate and recurrence rate between the two groups(P>0.05).Conclusion Compared with BCD regi-men,VRD regimen can improve clinical efficacy and quality of life in MM patients,and reduce the incidence of adverse reactions.
关键词
多发性骨髓瘤/来那度胺/环磷酰胺/硼替佐米/临床疗效/生活质量/不良反应
Key words
multiple myeloma/lenalidomide/cyclophosphamide/bortezomib/clinical efficacy/quality of life/ad-verse reaction
维普
万方数据